Ximbio

New Antibodies from Ximbio

We're pleased to provide our first Ximbio product update. Ximbio originates from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK. Ximbio operates as a business unit of CRT and focuses on all areas of biology. Our new website provides a central portal for the life science community to exchange knowledge and trade reagents.

Ximbio is pleased to introduce nine new monoclonal antibodies available for licence as hybridomas or purchase as purified antibodies.

For licensing and sales enquiries please email: enquiries@ximb.io or call +44 (0)20 3469 6449.

Technical datasheets for Ximbio’s expanding research tool portfolio can be accessed at www.ximb.io

Register Now >

	Anti-c-Met, clone 12.1 Applications: IHC IF IP WB Publications: PMID: 23859937 Clone 12.1 is specific for c-Met, a tyrosine receptor kinase which is activated by its ligand, hepatocyte growth factor. Activation of c-Met leads to a number of biological activities including motility, angiogenesis, morphogenesis, cell survival and cell regeneration. c-Met is abnormally activated in many tumour types.
	Anti-HHV-8 LNA-1, clone LN53 Applications: ELISA FACS IHC IP WB Publications (PMIDs): 15700034, 11577129, 11477117, 10233979, 10200299 This antibody reacts with latent nuclear antigen (LNA-1) of human herpesvirus-8 (HHV-8). HHV-8 has been found to be associated with three different diseases observed in AIDS patients; Kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. LNA-1 is recognized by most infected patient sera and is the basis of current immunofluorescence assays used in epidemiological studies of HHV-8 infection.
	Anti-Cytochrome P450 39A1, clone M30P6D6 Applications: ELISA IHC WB Publications (PMIDs):None CYP39A1 (cytochrome P450, family 39, subfamily A, polypeptide 1), also known as 24- hydroxycholesterol 7-α-hydroxylase localises to both the microsome and the endoplasmic reticulum. Using heme groups as cofactors, CYP39A1 is involved in the bile acid metabolism and is specifically expressed in liver.
	Anti-Cytochrome P450 26A1, clone F27P6A1 Applications: ELISA IHC WB Publications (PMIDs): 24608339, 16243809, 15897573 Mutations in CYP26A1 are associated with caudal agenesis and spina bifida. CYP26A1 is upregulated in adenomatous polyposis coli mouse adenomas, human FAP adenomas, human sporadic colon carcinomas, and in the intestine of adenomatous polyposis coli (apcmcr) mutant zebrafish embryo.
	Anti-RYK, clone F35P7D7F5 Applications: WB Publications (PMID):None Clone F35P7D7F5 reacts with RYK receptor-like tyrosine kinase. RYK may be a co-receptor of Wnt proteins such as WNT1, WNT3, WNT3A and WNT5A. RYK is involved in neuron differentiation, axon guidance, corpus callosum establishment and neurite outgrowth.
	Anti-hAPC, clone C-APC 28.9 Applications: IHC IF IP WB Publications (PMIDs): 15951972, 11283620 Clone c-APC 28.9 is specific for the adenomatous polyposis coli tumor suppressor gene, mutated in the inherited disease, familial adenomatous polyposis (FAP), and over 80% of colorectal cancers.
	Anti-TACE, clone D1 (A12) Applications: N Publications (PMIDs): 26010411, 23348744, 22792380, 21415364 TACE/ADAM17/CD156b is capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. Clone D1 (A12) was originally developed as a recombinant antibody and selected for its unique agonistic properties. Subsequently re-engineered with a human IgG backbone this “cross-domain” antibody provides a unique alternative to small molecule metalloprotease inhibition.
	Anti-TDP43, clone DB9 Applications: ELISA IHC WB Publications (PMID): Likely summer 2015 Clone DB9 reacts with neuroscience target TAR DNA-binding protein 43 (TDP43). TDP43 belongs to the hnRNP protein family and plays an important role in transcription, pre-mRNA splicing, mRNA stability and mRNA transport. Mutations in TDP43 have been associated with amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease and Alzheimer's disease.
	Anti-CLEC2, clone AYP1 Applications: FACS FITC IF IP N WB Publications (PMIDs): 25150298 Clone AYP1 is specific for CLEC2, a target shown to be raised in platelet-derived microparticles from patients with rheumatoid arthritis. CLEC2 can be used to screen for platelet activation in a wide variety of cardiovascular and inflammatory diseases.
	Anti-CLEC2, clone AYP2 Applications: WB Publications (PMIDs): 25150298 Clone AYP2 is specific for CLEC2, a target shown to be raised in platelet-derived microparticles from patients with rheumatoid arthritis. CLEC2 can be used to screen for platelet activation in a wide variety of cardiovascular and inflammatory diseases.